Chu Zhaohui, Lin Hao, Liang Xiaohua, Huang Ruofan, Zhan Qiong, Jiang Jingwei, Zhou Xinli
Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China, 200040; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 200032.
PLoS One. 2014 Nov 6;9(11):e111493. doi: 10.1371/journal.pone.0111493. eCollection 2014.
This study analyzed the clinicopathologic characteristics of typical medullary breast carcinoma (TMBC) in a cohort of Chinese patients.
We conducted a retrospective review of clinical data including general information, pathologic results, treatment regimens, and patient survival in cases of TMBC diagnosed between February 2004 and April 2011.
A total of 117 patients were enrolled, with a median age of 52 years (range, 28∼92 years). Stage I and II disease accounted for 31.6% and 61.6% of the cases, respectively. Hormonal receptor negative disease (estrogen receptor negative, 68.4%; progestogen receptor negative, 86.3%) was more prevalent in this population. Human epidermal growth factor receptor-2 (HER-2) positivity was 20.5%, while equivocal and HER-2 negative cases represented 16.2% and 63.2% of the cohort. The triple-negative, luminal, and HER-2 overexpressing subtypes constituted 44.4%, 31.6%, and 15.4% of the cases, respectively. The various TMBC subtypes showed no differences regarding tumor size, rates of lymph node(s) metastasis, TNM staging, treatment regimens, and 2-year recurrence rates. However, patients with triple-negative disease were more likely to be younger, when compared to those with luminal disease (P = 0.002). At a median follow-up of 56 months (range, 2-112 months), the 2-year disease-free survival and overall survival rates were 99.1% and 98.2%, respectively.
Early stage disease dominated the study cohort, and at two years after surgery, recurrence was extremely low. The heterogeneity of molecular subtypes was clearly shown, and no apparent differences were found among the clinicopathologic characteristics of the triple-negative, luminal, and HER-2 overexpressing subtypes.
本研究分析了一组中国患者中典型髓样乳腺癌（TMBC）的临床病理特征。
我们对2004年2月至2011年4月间诊断为TMBC的病例的临床资料进行了回顾性分析，包括一般信息、病理结果、治疗方案和患者生存情况。
共纳入117例患者，中位年龄为52岁（范围28～92岁）。Ⅰ期和Ⅱ期疾病分别占病例的31.6%和61.6%。激素受体阴性疾病（雌激素受体阴性，68.4%；孕激素受体阴性，86.3%）在该人群中更为普遍。人表皮生长因子受体2（HER-2）阳性率为20.5%，而可疑和HER-2阴性病例分别占队列的16.2%和63.2%。三阴性、管腔型和HER-2过表达亚型分别占病例的44.4%、31.6%和15.4%。各种TMBC亚型在肿瘤大小、淋巴结转移率、TNM分期、治疗方案和2年复发率方面无差异。然而，与管腔型疾病患者相比，三阴性疾病患者更可能年轻（P = 0.002）。中位随访56个月（范围2～112个月）时，2年无病生存率和总生存率分别为99.1%和98.2%。
早期疾病在研究队列中占主导地位，术后两年复发率极低。分子亚型的异质性明显，三阴性、管腔型和HER-2过表达亚型的临床病理特征无明显差异。
